Trelegy Ellipta® inhalation powder for COPD and asthma maintenance

What Trelegy Ellipta® Is and How It Works

Trelegy Ellipta® is a once‑daily inhalation powder that combines three medicines for long‑term control: an inhaled corticosteroid (fluticasone furoate), a long‑acting muscarinic antagonist (umeclidinium), and a long‑acting beta2‑agonist (vilanterol). It is used for maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema, and for maintenance treatment of asthma in adults. It is not a rescue inhaler for sudden breathing problems.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We partner with vetted pharmacies to source authentic brand medications, offer a broad selection, and keep value‑focused pricing in view.

This trelegy inhaler delivers a single dose with each opening of the cover. The three components work together: fluticasone reduces airway inflammation; umeclidinium relaxes airway smooth muscle via muscarinic blockade; and vilanterol provides bronchodilation through beta2‑receptor stimulation. Many adults prescribed Trelegy Ellipta for asthma or COPD notice steadier control when taken daily as directed.

Dosage and Usage

• Usual dose and cadence: One inhalation once daily, taken at the same time each day. Do not take more than one inhalation in 24 hours.
• Trelegy dose for COPD: 100/62.5/25 mcg once daily.
• Trelegy dose for asthma: 100/62.5/25 mcg or 200/62.5/25 mcg once daily. The trelegy dose per day is one inhalation.
• Not for acute symptoms: Use a fast‑acting rescue inhaler for sudden wheeze or shortness of breath.
• Rinse after use: Rinse mouth and spit after each dose to lower the chance of thrush.
• How to use (Ellipta device): Remove the inhaler from the foil tray when ready to start. Open the cover fully until it clicks to load a dose. The counter should decrease by one. Do not shake. Breathe out fully away from the mouthpiece. Seal lips around the mouthpiece and inhale a long, steady, deep breath. Remove the inhaler and hold breath as long as comfortable. Breathe out slowly. Close the cover. Do not block the air vent. Do not take an extra inhalation.
• Missed dose: If a dose is missed, skip it and take the next dose at the usual time. Do not double up.

• Storage: Keep at 20–25°C (68–77°F); excursions 15–30°C (59–86°F). Store dry. Keep the cover closed.
• Foil tray: Keep sealed until first use. Discard 6 weeks after opening the tray or when the counter reads 0, whichever comes first. Record the opening date.
• Handling: Do not wash the device. If needed, wipe the mouthpiece with a dry tissue. Keep away from moisture.
• Travel: Carry in a cabin bag, not checked luggage. Avoid extreme heat or cold. Keep the device dry and protected. Bring a rescue inhaler on trips.

Benefits and Savings

This trelegy medication combines anti‑inflammatory and dual bronchodilator actions in one inhaler. Many adults experience improved lung function, fewer exacerbations, and better symptom control. Once‑daily dosing and a dose counter simplify adherence. The breath‑actuated Ellipta design needs no priming and suits a wide range of inspiratory flows.

Value matters alongside control. Many customers save 60–80% vs typical U.S. prices. If you are comparing the trelegy ellipta price across options, CanadianInsulin offers transparent, value‑focused choices and prompt, express, cold‑chain shipping.

See our promotions page for current offers, including any trelegy coupon if available.

Side Effects and Safety

• Headache, back pain, joint pain
• Sore throat, hoarseness, cough
• Nasal congestion or sinus infection
• Oral thrush (yeast infection), mouth irritation
• Upper respiratory tract infection
• Dry mouth or bitter taste
• Tremor, fast heartbeat, palpitations
• Nausea, stomach discomfort
• Urinary retention in susceptible patients

Serious or rare risks include pneumonia in COPD, paradoxical bronchospasm, allergic reactions, reduced adrenal function with high steroid exposure, decreased bone mineral density, glaucoma or cataracts, worsening of narrow‑angle glaucoma or urinary retention, changes in blood sugar or potassium, and cardiovascular effects. Contraindicated in severe milk protein allergy. Avoid combining with other long‑acting bronchodilators in the same classes. Ask a healthcare provider about interactions such as strong CYP3A4 inhibitors, beta‑blockers, MAO inhibitors, or additional anticholinergics.

Onset Time

Bronchodilation from the vilanterol and umeclidinium components can begin within hours of the first dose. Some patients notice easier breathing the same day. Anti‑inflammatory effects from fluticasone build with daily use. Lung function improvements generally emerge over 1–2 weeks. Exacerbation reduction becomes clearer over 4–12 weeks and with continued maintenance therapy.

Compare With Alternatives

Some adults step up to triple therapy when dual therapy is not enough. An ICS/LABA such as Advair Diskus® or Symbicort® offers two agents instead of three. These can suit patients with milder control needs or specific response patterns. A LAMA such as Spiriva Respimat Inhaler® may be added to ICS/LABA in COPD, but Trelegy integrates all three classes in one device. Choice depends on diagnosis, severity, and prior response.

Compared with dual therapy, Trelegy Ellipta can improve lung function and reduce moderate to severe COPD exacerbations in appropriate adults. In asthma, stepping up from an ICS/LABA to Trelegy may help those who remain symptomatic. Device preference and inspiratory flow also guide selection.

Combination Therapy

• Use with a short‑acting beta2‑agonist (SABA) rescue inhaler as needed for sudden symptoms.
• Do not combine with other LABA or LAMA maintenance inhalers to avoid duplication.
• For COPD, some adults may also use roflumilast or macrolide prophylaxis per specialist guidance.
• Allergy control (e.g., intranasal steroids or antihistamines) can complement asthma plans when indicated.
• Vaccinations and pulmonary rehab support overall COPD management as advised by clinicians.

Patient Suitability and Cost‑Saving Tips

Trelegy Ellipta is for adults with COPD maintenance needs, including chronic bronchitis or emphysema. It is also for adults with asthma who need ongoing control and are not well controlled on ICS/LABA therapy. It is not for children. It does not treat acute bronchospasm. Candidates need to be able to perform a long, steady, deep inhalation through the device.

Those with severe milk protein allergy should not use this inhaler. Caution is advised in patients with glaucoma, cataracts, urinary retention, prostate enlargement, arrhythmias, hypertension, osteoporosis, tuberculosis, or immunosuppression. Discuss past pneumonia, frequent exacerbations, and current inhaler technique with a clinician to tailor therapy.

To reduce costs, consider multi‑month quantities, coordinate household orders, and place refills before running low so shipping is efficient. Keep the inhaler dry and track the counter to avoid waste. CanadianInsulin lists available strengths clearly so you can match your prescribed dose when ordering.

Authoritative Sources

FDA Prescribing Information and Medication Guide for Trelegy Ellipta

GSK Patient and Prescribing Information

Health Canada Drug Product Database: Trelegy Ellipta

Order Trelegy Ellipta from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace medical advice from your healthcare professional. Always follow the prescribing information and your provider’s guidance.